PARTNER WITH KLEA PHARMA
Bring your products to the MEA market through pharmaceutical licensing and distribution
The Middle East and Africa is one of the fastest-growing specialty healthcare regions in the world
PARTNER WITH KLEA PHARMA
Capture disproportionate share by entering with a local expert
Here is what Klea Pharma brings
01
European governance
Our parent, Klea Holding, is listed on Euronext Growth Paris, assuring our partners transparency, and the long-term stability needed to support sustainable partnerships.
02
Healthcare ecosystem
Investment, diagnostics and pharma brought together within one integrated platform to expand access and drive growth within the region.
03
Regional execution
In-house regulatory, medical, pharmacovigilance and commercial teams, supporting a resilient pharmaceutical supply chain from molecule to prescriber.
04
Proven commercial engine
Experienced commercial teams supported by a strong network of trusted partners providing the expertise, required to build and grow brands successfully.
05
Scalable growth platform
A proven UAE foundation, supported by strong distribution capabilities across the GCC and Levant, with a clear expansion roadmap into Subsaharian Africa.
Markets we cover
One agreement with Klea opens a corridor of high-growth markets, backed by European governance and in-house execution.
Europe
M&A and strategic partnerships base
Gulf (GCC)
UAE HQ · Qatar · Kuwait · Bahrain · Oman · Saudi Arabia
North Africa
Egypt · Morocco · Algeria · Tunisia
West Africa
French-speaking Africa · Ghana · Nigeria
East Africa
Kenya · Tanzania · Ethiopia · Uganda
Discover our partnership models
From exclusive distribution to pharmaceutical licensing and co-promotion, Klea structures the right partnership for your pharmaceutical supply chain and go-to-market strategy.
Exclusive distribution
Flagship registered products ready for launch
- Klea takes MEA-exclusive distribution rights
- Ex-works purchase at agreed transfer price
- Klea funds local registration, marketing, sales
- Minimum annual volumes and forecast commitments
Pharmaceutical license and supply
Pre-approval or high-margin specialty assets
- Milestone-based payments
- Royalty on in-market net sales (negotiable)
- Klea holds marketing authorisation and TM locally
- Joint-steering committee on brand strategy
Co-promotion
Strategic partners seeking deep market presence through pharmaceutical co-promotion
- Shared P&L, shared investment, shared upside
- Dedicated co-branded sales force possible
- Technology / manufacturing transfer optional
- Multi-product framework agreements welcome
- Second brand upon sunset
Get in touch
Tell us about your company and what you'd like to bring to the region.